CytoDyn set to deliver its leronlimab treatment to critically ill coronavirus (COVID-19) patients in the Philippines

CytoDyn set to deliver its leronlimab treatment to critically ill coronavirus (COVID-19) patients in the Philippines

CytoDyn Inc (OTCQB:CYDY) announced it is delivering its drug leronlimab to a Philippine hospital to be administered to another 28 critically ill coronavirus (COVID-19) patients under a new Compassionate Special Permit (CSP). The company also said it is negotiating the potential future delivery of 100,000 vials to the Philippines for additional CSP use. “Based upon the speedy recovery of the first COVID-19 CSP patient in the Philippines, we are coordinating very closely with Chiral and the regulators to ensure we are expediting as much leronlimab as needed,” CytoDyn CEO Nader Pourhassan said in a statement. READ: CytoDyn has multiple shots on goal with its flagship drug Vyrologix to treat for HIV, various cancers and even coronavirus “We remain hopeful that all of these coordinated efforts will continue to expand the availability of leronlimab to the Philippines,” Pourhassan added. CytoDyn noted that its commercial partner in the Philippines, Chiral Pharma Corporation, is working closely with the Philippine FDA and the hospital. Leronlimab (PRO 140) is a C-C chemokine receptor type 5 (CCR5) antagonist with potential multiple therapeutic indications. CCR5 hampers the ability of a virus to infiltrate immune cells.   Aside from COVID-19, the US Food & Drug Administration (FDA) has granted Fast Track designation to CytoDyn for two potential indications of leronlimab for critical illnesses. The first is a combination therapy with HAART for HIV-infected patients and the second is for metastatic triple-negative breast cancer. Contact Sean at sean@proactiveinvestors.com

Post a Comment